MedTrace Logo

A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects

NCT03516331 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-11-02

No results posted yet for this study

Summary

This is an 2-part study. Part 1 will assess the safety, tolerability and pharmacokinetics of single doses of FDL176 with and without co-administration of FDL169. Part 2 will assess the safety, tolerability and pharmacokinetics of repeated doses of FDL176 with and without co-administration of FDL169 .

Conditions

Interventions

DRUG

FDL176 & FDL169 coadministration

CFTR corrector and potentiator

Sponsors & Collaborators

  • Flatley Discovery Lab LLC

    lead OTHER

Principal Investigators

  • Claudia Ordonez, MD · Flatley Discovery Lab

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2018-08-22
Completion
2018-08-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516331 on ClinicalTrials.gov